期刊文献+

老年人下呼吸道革兰阴性杆菌感染耐药机制研究

Study on antimicrobial resistance mechanism of gram-negative bacillus infections of respirarory tract in senile paiens
下载PDF
导出
摘要 目的研究本院老年人下呼吸道感染革兰阴性杆菌产灭活酶耐药机制。包括超广谱β内酰胺酶(ESBLs)、高产头孢菌素酶(AmpC)和金属酶。通过对临床常见致病菌大肠埃希菌、肺炎克雷伯菌、阴沟肠杆菌、铜绿假单孢菌、不动杆菌和嗜麦芽窄食单胞菌等的检测结果分析,掌握本院老年患者下呼吸道感染主要病原菌的耐药规律及主要基因型,为临床经验治疗提供参考依据。方法单纸片扩散初试产ESBL菌株,用双纸片增效确认试验或自动细菌鉴定和药敏系统(VITEK)确定ESBL 菌株;用改良三维法检测去阻遏头孢菌素酶;Etest金属酶试条测定铜绿假单孢菌产金属酶的情况。用等电聚胶和测序方法对ESBL阳性株作分子基因分型。结果 80株肺炎克雷伯菌及143株大肠埃希菌产ESBL(超广谱β内酰胺酶)频率分别为27.5%和28.7%,CTX-M基因型分别占48%和56%。124株阴沟肠杆菌中有21.8%单独高产AmpC酶,8.1%单独产ESBL,3.2%即产ESBL又高产AmpC酶。71株耐亚胺培南的绿脓假单胞菌中有18.3%产金属β内酰胺酶。结论产ESBL、高产AmpC酶和金属β内酰胺酶是住院老年患者下呼吸道感染难以治愈的重要因素。CTX-M基因型是我院ESBLs流行的主要基因型。 OBJECTIVE To investigate the resistance mechanism of no molecule on the elderly lowe respiratory infection. METHODS β-lactamases of the isolates by double-disk increase. three-dimensional extract test. VITEK and Etest. RESULTS Among 80 k. Pneumonia and 143 E.coli 27.5% and 28.7% produced ESBL respectively by three-dimensioal extract testand 48% and 56% are CTX-Mgenetyperespectively. Among 124 E.cloacae isolates, 21.8% produced olny high--level AmpCβ-lactamases, 8.1% produced only ESBL, 3.2% produced both high-leve AmpCβ-lactamases and ESBL. Among 71 strains wieh resistent Impenem of pseudomonas aeruginosa 18.3% produced metallo β-lactamases. CONCLUSIONS The result showed that the strains produced expamded spectrum β-lactamases (ESBL), high-level AmpCβ-lactamases and metallo-β-lactamases are Important cause for lower respira tory infection on the elderly in-patient.
机构地区 卫生部北京医院
出处 《临床药物治疗杂志》 2003年第3期13-16,共4页 Clinical Medication Journal
关键词 老年人 下呼吸道感染 革兰阴性杆菌 耐药性 致病菌 抗生素 Elderly lower respiratory infection gram-negtive bacilli study on resistance mechnism
  • 相关文献

参考文献7

二级参考文献18

  • 1Livermore DM, Williams JD. β-lactams: mode of action and mechanisms of bacterial resistance. In: Lorian V, eds. Antibiotics in laboratory medicine. 4th ed. Baltimore:Williams & Wilkins, 1996. 502-578.
  • 2Sanders CC. β-lactamase of gram negative bacteria: new challenges for new drugs. Clin Infect Dis, 1992,14:1089-1099.
  • 3Naumiuk L, Samet A, Dziemaszkiewicz E. Cefepime in vitro activity against derepressed extended-spectrum β-lactamase(ESBL)-producing and non-ESBL-producing Enterobacter cloacae by a disc diffusion method. J Antimicrob Chemother, 2001,48:321-322.
  • 4National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 9th informational supplement(M100-S9). Wayne:NCCLS,1999.
  • 5Coudron PE,Moland ES, Thomson KS. Occurrence and detection of AmpC β-lactamases among Escherichia coli,Klebsiella pneumoniae,and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol, 2000, 38:1791-1796.
  • 6Tzelepi E, Giakkoupi P, Sofianou D, et al. Detection of extended-spectrum β-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J Clin Microbiol, 2000,38:542-546.
  • 7Chanal C, Sirot D, Romaszko JP, et al. Survey of extended-spectrum β-lactamases among Enterobacteriaceae. J Antimicrob Chemother, 1996, 38:127-132.
  • 8Coudron PE,Moland ES, Sanders CC. Occurrence and detection of extended-spectrum β-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. J Clin Microbiol, 1997, 35:2593-2597.
  • 9Tseng CY,Liu PY,Wu WL,et al.Comparison of detection of extended-spectrum beta-lactamases by agar dilution method,E-test ESBL screen and double disk test[J].J Microbiol Immunol Infect 1998,31(2):90-94.
  • 10Sirot D.Extended-spectrum plasmid-mediated β-lactamases[J].J Antimicrob Chemot her,1996,(SupplA):19-34.

共引文献339

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部